Supernus Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
SUPN Supernus Pharmaceuticals Inc
CRS Carpenter Technology Corp
AMWL American Well Corp
DGLD.NV Credit Suisse AG
HMPQ HempAmericana Inc
$SPMCKCP S&P GSCI Coffee Multiple Contract (U
WYNN Wynn Resorts Ltd
BAC Bank of America Corp
KNDI Kandi Technologies Group Inc
$RFTREES Refinitiv Eurozone ESG Select Index
Go

Health Care : Pharmaceuticals | Small Cap Blend
Company profile

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

Postmarket

Last Trade
Delayed
$29.20
-0.02 (-0.07%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$29.22
Day's Change
0.43 (1.49%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
29.80
Day's Low
28.49
Volume
(Above Average)
Volume:
690,133

10-day average volume:
582,146
690,133

SUPN's position in the Pharmaceuticals industry

Industry PeersSUPNPCRXPBHAMRXAMPH

Summary

Company ProfileSupernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR...
Pacira BioSciences, Inc., formerly Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of...
Go to PCRX summary
Prestige Consumer Healthcare Inc., formerly Prestige Brands Holdings, Inc. is engaged in the marketing, sales and distribution of over-the-counter healthcare products. The Company operates through...
Go to PBH summary
Amneal Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in...
Go to AMRX summary
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and...
Go to AMPH summary
52-Week Change

VS. INDUSTRY
18.88%
78.24%
-8.82%
-5.85%
-6.69%
Market Cap

VS. INDUSTRY
$1.5B
$3.4B
$1.9B
$1.5B
$914.9M
Beta

VS. INDUSTRY
1.3
1.2
0.7
1.3
0.8
Dividend Yield

VS. INDUSTRY
--
--
--
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
11.95x
27.17x
11.74x
--
143.25x
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$477.3M
$421.1M
$959.6M
$1.9B
$337.3M
Profit Margin

VS. INDUSTRY
27.09%
29.95%
17.03%
-5.29%
2.27%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
--
--
13.37%
--
--
Revenue Growth (TTM)

VS. INDUSTRY
16.91%
6.95%
0.73%
8.88%
2.63%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.